A new biotech company out of Massachusetts is levering human genetics and genome editing to “turn the tide” of coronary artery disease (CAD), experimenting with CRISPR to stop CAD from ever developing in at-risk individuals.

The FDA has cleared two new drugs, tafamidis and tafamidis meglumine, for the treatment of cardiomyopathy caused by a rare disorder known as transthyretin-mediated amyloidosis (ATTR-CM).

The migraine medication galcanezumab might protect against adverse CV events in patients taking the drug for episodic headaches, according to research presented at the American Academy of Neurology’s 2019 meeting in Philadelphia.

Vivimed Life Sciences on May 3 announced a voluntary recall of 19 lots of losartan potassium tablets, making it the third company in two weeks to issue a recall of the blood pressure (BP) drug.

A Harvard cardiologist and his team have developed an experimental genetic test for predicting obesity, NPR reports.

Long-term exposure to low doses of ionizing radiation raises a person’s risk for developing high blood pressure, according to a Hypertension study of more than 22,000 nuclear facility workers in Russia.

A study of more than 750 kids who were followed into their thirties has linked oral infections in childhood to CVD later in life—particularly subclinical carotid atherosclerosis.

Coronary artery bypass grafting (CABG) surgery beat out stent placement with percutaneous coronary intervention (PCI) in a recent study of patients with multivessel coronary artery disease. Patients saw lower risks of death, hospital readmission and revascularization with the former procedure.